Trial Profile

To compare the incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in patients with metastatic melanoma treated with antiprogrammed cell death-1, BRAF inhibitor monotherapy or dabrafenib and trametinib combination therapy (CombiDT)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; Dabrafenib/trametinib (Primary) ; Trametinib (Primary)
Indications Malignant melanoma
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com